Context: Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS). Metformin may also benefit future health by modulating increased metabolic stress during pregnancy.
impairment and increased risk of pregnancy complications. Data from meta-analyses show a threefold increase in gestational diabetes mellitus (DM) among women with PCOS (4) (5) (6) .
Pregnancy entails metabolic and homeostatic alterations and a physiological increase in insulin resistance, particularly during the third trimester. In a large cohort of women, a history of pregnancy complications such as preeclampsia, gestational diabetes, and giving birth to a small-for-gestational-age infant were indicators of an increased risk of cardiovascular disease (CVD) later in life (7) . Awareness of these trajectories provides an opportunity for early identification of women at risk.
Excessive weight gain in pregnancy has a negative effect on obstetric outcome (8) (9) (10) . Women with high gestational weight gain have a threefold increased risk of being overweight at first prenatal visit in a consecutive pregnancy compared with the risk in women with normal or low gestational weight gain (11) . Excessive postpartum weight retention at the end of the first year postpartum is a predictor for being overweight 15 years later (12) . We previously reported that women with PCOS randomly assigned to metformin 2 g/d gained less weight during pregnancy (13) .
Insulin resistance, although not a criterion for PCOS, affects the majority of women with the syndrome. Among hirsute women with PCOS in a Danish cohort, increased fasting insulin level was found in 28% of women with body mass index (BMI) #25 kg/m 2 and in 74% of women with BMI .25 kg/m 2 (14) . Hyperandrogenism seems to worsen insulin resistance in PCOS, with insulin resistance found in 43% of hyperandrogenic women compared with 14% of normoandrogenic women (15) . Metformin is a multipotent drug that exerts its effect on several tissues that are sensitive to insulin, such as liver, skeletal muscle, and adipose tissue. The Endocrine Society guideline on PCOS recommends lifestyle interventions such as physical exercise and weight loss as primary treatment of overweight and obesity in PCOS. Metformin is recommended as second-line treatment when type 2 DM or impaired glucose tolerance is present and lifestyle intervention is insufficient to improve metabolic dysfunction. In addition, metformin is recommended for menstrual irregularity in women with PCOS when treatment with hormonal contraceptives is contraindicated or not tolerated (16) . Worldwide, metformin is prescribed in the first trimester and onward in an attempt to improve pregnancy outcome in PCOS. Metformin may also benefit future maternal health by modulating increased metabolic stress during pregnancy
To our knowledge, prospective data regarding postpartum metabolic health in women with PCOS have not been published. In the current study, we aimed to explore possible effects of metformin treatment during pregnancy on long-term metabolic health.
Materials and Methods
The current study is a follow-up to a randomized, controlled, double-blind, multicenter trial. Mothers who participated in the Metformin in Pregnant PCOS Women Study (the PregMet Study) (17) from 2005 to 2009 were eligible for participation in the follow-up. Women with PCOS were randomly assigned to metformin or placebo from the first trimester to delivery to assess whether metformin reduced pregnancy complications.
Study design

The PregMet Study
In all, 257 women with 274 pregnancies were included at 11 study centers in Norway: three university hospitals, seven local hospitals, and one gynecological specialist practice. Randomization, blinding, and examinations are described elsewhere (17) . Inclusion criteria for the PregMet Study were (1) PCOS diagnosed according to the Rotterdam criteria (3), (2) age 18 to 45 years, (3) gestational age between 5 and 12 weeks, and (4) a viable singleton fetus shown on ultrasonography. The participants received counseling on lifestyle and diet at inclusion, before randomization to metformin (2 g/d) or placebo. To counteract possible metformin effects on folate or vitamin B 12 levels, the participants were advised to take 0.8 mg of folate and one multivitamin tablet daily throughout pregnancy.
The follow-up study
From April 2014 to July 2016, a total of 239 women were invited to participate in the follow-up. The inclusion criterion was participation in the PregMet Study. Exclusion criteria were ongoing pregnancy and breastfeeding (Fig. 1) . Participants who dropped out (n = 12), miscarried (n = 3), or lost their children (n = 3) were not invited. Seventeen of the women participated twice in the PregMet Study. When women participated twice and were randomized equally, data from the first participation were recorded; when they were randomized once to metformin and once to placebo, the data from the metformin-exposed pregnancy were used. Nonresponders received two reminders about 1 to 2 months and 6 to 7 months after the first letter. In all, 131 women (55%) agreed to participate in the follow-up. One hundred seventeen women met for a physical examination and interview, whereas 14 were interviewed by phone and gave self-reported data. Two medical students and a trained midwife examined the participants and collected the data. Standardized interviewer-administered questionnaires were used to obtain self-reported data on former medical and gynecological/obstetric history, contraceptives, ethnicity, education, civil status, smoking, physical activity, and current use of metformin.
Blood pressure (BP) was measured three times, 2 minutes apart, with digital devices, with the participant in a sitting position after at least 15 minutes of rest in a chair. The mean of the second and third measurements was calculated. Height and waist and hip circumferences were measured manually and rounded off to the closest 0.5 cm. Body composition and weight were measured using bioelectrical impedance (InBody 720; BIOSPACE, Seoul, South Korea). The examination was performed with the participant wearing light and snug clothes and no shoes. InBody gives an estimate of total body fluids, proteins, minerals, and fat and was validated against dualenergy X-ray absorptiometry.
Blood samples were drawn from an antecubital vein between 0800 and 1100 hours after an overnight fast. All analyses except insulin were performed directly, using standard procedures at St. Olavs Hospital, Trondheim, Norway. Insulin was analyzed at Oslo University Hospital, Aker, Norway. The homeostatic model assessment (HOMA) index was computed as [fasting glucose (mmol/L) 3 fasting insulin concentration (mU/L)] /22.5. HOMAb was calculated using the following formula: 20 3 fasting insulin (mU/L)/fasting glucose (mmol/L) 2 3.5. The prevalence of metabolic syndrome (MetS) was estimated according to the Rotterdam consensus (3) . Three of the following five criteria were required: waist circumference .88 cm; triglycerides $150 mg/dL (1.7 mmol/L); high-density lipoprotein (HDL) #50 mg/dL (1.3 mmol/L); systolic BP $130 mm Hg and/or diastolic BP $85 mm Hg; and fasting glucose 110 to 126 mg/dL (6.11 to 6.99 nmol/L) and/or 2-hour oral glucose tolerance test glucose 140 to 199 mg/dL (7.78 to 11.04 nmol/L). The more widely applicable guideline, the National Cholesterol Education Program-Adult Treatment Panel III definition, requires the presence of at least three of the following five criteria: waist circumference .88 cm; triglycerides $150 mg/dL (1.7 mmol/L) or drug treatment of elevated triglycerides; HDL #50 mg/dL (1.3 mmol/L) or drug treatment of reduced HDL cholesterol; systolic BP $130 mm Hg and/or diastolic BP $85 mm Hg or treatment of elevated BP; and fasting glucose $100 mg/dL (5.6 nmol/L).
Participants were asked if they had been diagnosed with type 2 DM, hypertension, CVD, or depression.
Statistical analyses
Statistics were performed with SPSS version 24 (IBM Corp., Armonk, NY). Data were reported as mean 6 standard deviation or absolute numbers (percentages). Differences between study groups were assessed with two-tailed t tests for independent samples. Fisher exact test was used for evaluation of discrete data. To adjust for multiple testing, we considered significance as a two-tailed P value , 0.01.
Ethical approval
Written informed consent was obtained from each participant before inclusion, and the Declaration of Helsinki was followed throughout the study. The Regional Committees for Medical and Health Research Ethics Mid-Norway approved the current study (04.04.2014, reference number: 2014/96).
Results
In all, 131 of 239 invited participants (55%) in the PregMet Study agreed to participate in this followup. The only difference between the metformin and the placebo groups at baseline (i.e., at inclusion in the PregMet Study) was lower total cholesterol level in the placebo group (Table 1) . Women who participated in the follow-up and those who declined were comparable at baseline, except for a tendency toward more smokers among those who declined, n 5 7 vs 15 (P = 0.051) (data not shown). In the PregMet Study, 80% of the participants took .85% of the study medication.
We found no difference in weight-gain (from the first trimester of pregnancy to follow-up), BMI, waist/hip ratio, BP levels, body composition, fasting lipid levels, fasting glucose levels, or HOMA index when comparing metformin-treated women with placebo-treated women at follow-up ( Table 2) . Prevalence of MetS, type 2 DM, hypertension, CVD, and depression was comparable between the metformin and placebo groups. Participants with hyperandrogenism were comparable to those without hyperandrogenism regarding waist circumference, BP, fasting lipids, glucose, and HOMA index (data not shown). Education level, civil status, and parity were similar in both groups at follow-up (Table 3) .
Discussion
Metformin use from the first trimester and throughout pregnancy did not modify maternal metabolic profile at 7.7 years postpartum. Postpartum yearly weight increase in women with PCOS was relatively low, independent of randomization.
Strengths of the study
This study prospectively assessed the long-term metabolic profile in a well-characterized cohort of women with PCOS after randomization to metformin or placebo treatment during pregnancy. Participants in the followup were representative of the original study population.
Limitations of the study
Participants in this follow-up were relatively young to experience serious complications of MetS, such as CVD. Risk factors of CVD may occur at this age and may potentially be modified by metformin intervention. A 55% participation rate is less than we had hoped for, but the percentage is in accordance with that of other clinical follow-up studies. Further assessment of glucose tolerance by an oral glucose tolerance test would be preferable, but this was not possible because of limited resources and for practical reasons.
The metformin effect
We found no difference in weight gain from the first trimester of pregnancy to the current follow-up on the basis of randomization. Women randomly assigned to metformin gained less weight during pregnancy than those randomly assigned to placebo. However, maternal BMI increase from the first trimester to 1 year postpartum was higher in the metformin group (13) . These findings may be explained by weight homeostasis mechanisms restoring prepregnancy weight (18) . Interestingly, the average annual weight gain of 0.25 kg (0.44 kg when eight cases of bariatric surgery were excluded) in the follow-up period is relatively small in the current study compared with the background population. In a Norwegian population-based cohort, mean 11-year weight gain was 7.0 kg (0.64 kg/y) in those aged 30 to 39 years (19) . A higher baseline weight (mean, 80.0 kg) in women with PCOS compared with that of the Norwegian cohort (mean, 64.1 kg) may partly explain this observation. In an Australian communitybased longitudinal cohort of women in their 20s with PCOS, a 10-year weight gain of 6.6 kg (0.66 kg/y) was reported (20) . Women participating in the present follow-up were older. Moderate weight increase in the fourth decade of life onward might point to a different pattern of weight changes through life in women with PCOS, who are more susceptible to weight gain in adolescence and the early reproductive years. Another possible explanation may be that all participants (metformin and placebo groups) received counseling on lifestyle and diet when entering the original study. Both the counseling itself and the timing of it, in early pregnancy, might have had a lasting effect on lifestyle and weight management.
Contrary to our assumptions, the lower weight gain and metformin treatment as such during pregnancy did not affect maternal metabolic risk factors or lower the trajectory of insulin resistance 7.7 years postpartum. Women with PCOS were reported to have higher gestational weight gain than controls (21) . In nonobese women without PCOS, measurement of maternal insulin concentration in the upper quartile in early pregnancy was associated with increased gestational weight gain and higher postpartum weight retention (22) . Insulin resistance was reported to remain more pronounced 18 months postpartum in women with PCOS than in women without PCOS but with gestational DM (23) . According to the "metabolic memory" theory, in patients with type 2 DM, early intensive glycemic control is proposed to prevent high plasma glucose levels from triggering the known mechanisms of endothelial damage, such as oxidative stress, nonenzymatic glycation of proteins, epigenetic changes, and chronic inflammation. In in vitro studies, metformin, among other pharmaceutical interventions used to prevent long-term consequences of hyperglycemia, showed a strong inhibitory effect on the formation and accumulation of advanced glycation end products after nonenzymatic glycation (24) . One could hypothesize that in addition to lowering gluconeogenesis, increasing peripheral glucose use, and delaying glucose absorption, metformin has beneficial effects in suppressing progression of hyperglycemia-induced metabolic memory changes during the pregnant state.
Participants in the PregMet Study were diagnosed according to the Rotterdam criteria, and 72% presented with a phenotype that included hyperandrogenism. No difference in metabolic risk factors were detected between hyperandrogenic vs normoandrogenic women at follow-up (data not shown). The prevalence of MetS, type 2 DM, and CVD was low in the current study, as could be expected at a mean age of 37 years. Data on the risk of hard end points such as CVD in postmenopausal women with PCOS is diverging. Some studies suggest that protective factors are activated, prohibiting increased CVD risk factors from translating to CVD (25) .
Conclusion
At follow-up 7.7 years postpartum, the weight and metabolic health of women with PCOS were not influenced by metformin use in pregnancy. Weight increase in the fourth decade of life in women with PCOS was less than that in the general population. 
